MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$2,824K
Free Cash flow
-$2,123K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of series...
Accounts receivable
Loss (gain) on revaluation of wa...
Others
Negative Cash Flow Breakdown
Net loss
Principal payments under notes p...
Deferred revenues
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Changes in provision for credit losses on accounts receivable
-
-42
-13
5
Net loss
-6,885
-4,674
-1,421
-5,600
Depreciation and amortization
454
451
367
755
Loss on impairment of intangible asset
0
570
0
180
Changes in provision for credit losses on accounts receivable
323
-
-
-
Loss (gain) on revaluation of warrant liabilities
-727
0
0
1
Finance cost associated with warrant issuance
145
-
-
-
Loss on impairment of right-of-use asset
89
-
-
-
Stock-based compensation expense
114
783
234
457
Loss on modification of warrant
-
0
0
0
Common stock contribution to 401 plan
0
72
64
15
Unrealized loss (gain) on foreign currency transactions
-239
-4
4
1,965
Accounts receivable
-2,423
1,099
1,507
-3,052
Inventories
-168
-112
-494
881
Prepaid expenses and other assets, current and noncurrent
115
-260
283
164
Accounts payable
679
-232
216
-121
Accrued, lease and other liabilities, current and noncurrent
-188
-348
-38
-716
Deferred revenues
-296
-188
-170
-425
Net cash used in operating activities
-2,123
-4,331
-2,061
-5,409
Acquisition of property and equipment
0
126
12
50
Net cash used in investing activities
0
-126
-12
-50
Principal payments under notes payable
313
312
313
625
Retirement of term loan-Term Loan
-
0
2,000
-
Proceeds from issuance of common stock, net
-
3,232
-48
914
Proceeds from issuance of series b convertible preferred stock and january 2026 private placement warrants, net
5,265
-
-
-
Proceeds from exercise of warrants, net
0
0
0
3,856
Proceeds from issuance of convertible promissory note, net-Promissory Note
-
1
1,924
-
Net cash provided by financing activities
4,952
2,921
-437
4,145
Effect of exchange rate changes on cash
-5
-17
-10
63
Net increase in cash
2,824
-1,553
-2,520
-1,251
Cash and restricted cash at beginning of period
1,169
2,722
6,493
-
Cash and restricted cash at end of period
3,993
1,169
2,722
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
series b convertible...
$5,265K
Net cash provided by
financing activities
$4,952K
Canceled cashflow
$313K
Net increase in cash
$2,824K
Canceled cashflow
$2,128K
Principal payments under
notes payable
$313K
Accounts receivable
-$2,423K
Loss (gain) on
revaluation of warrant...
-$727K
Accounts payable
$679K
Depreciation and
amortization
$454K
Changes in provision for
credit losses on...
$323K
Unrealized loss (gain) on
foreign currency...
-$239K
Inventories
-$168K
Finance cost associated
with warrant...
$145K
Stock-based compensation
expense
$114K
Loss on impairment of
right-of-use asset
$89K
Net cash used in
operating activities
-$2,123K
Effect of exchange rate
changes on cash
-$5K
Canceled cashflow
$5,361K
Net loss
-$6,885K
Deferred revenues
-$296K
Accrued, lease and other
liabilities, current and...
-$188K
Prepaid expenses and
other assets, current...
$115K
Buy us a coffee
EKSO BIONICS HOLDINGS, INC. (EKSO)
EKSO BIONICS HOLDINGS, INC. (EKSO)